比美吉珠单抗在成人中轴型脊柱关节炎或银屑病关节炎患者中的长期安全性:整合IIb/III期临床研究汇总结果
汇总六项IIb/III期研究评估比美吉珠单抗(BKZ)治疗中轴型脊柱关节炎(axSpA)和银屑病关节炎(PsA)的长期安全性。axSpA组848例(2034.4患者年),PsA组1407例(2590.8患者年)。总体耐受性良好,两组不良事件发生率相当且长期稳定,未发现新的安全性信号。
要点
- axSpA与PsA组治疗中出现的不良事件发生率分别为136.9/100患者年和139.6/100患者年。
- 口腔念珠菌病发生率axSpA组3.7/100患者年、PsA组4.2/100患者年,大多为轻中度。
- 未报告系统性真菌感染或活动性结核病例,未发现新的安全性信号。
核心结论
- 总体而言,BKZ表现出良好的耐受性,axSpA与PsA队列的治疗中出现的不良事件发生率相当,并在延长治疗期间保持稳定。
- 未发现新的安全性信号。
研究设计与样本
- 汇总六项IIb/III期整合研究的安全性数据,纳入接受至少1剂BKZ 160 mg每4周一次的患者,报告至III期2022年7月数据截止。
- axSpA安全性汇总纳入848例患者(BKZ总暴露2034.4患者年),PsA安全性汇总纳入1407例患者(总暴露2590.8患者年)。
- 治疗中出现的不良事件采用每100患者年暴露调整发生率(EAIR/100 PY)报告。
主要发现
- 治疗中出现的不良事件EAIR/100 PY在axSpA组为136.9、PsA组为139.6;因不良事件停药率低(axSpA组2.7/100 PY,PsA组3.1/100 PY)。
- 报告最多的三种不良事件为SARS-CoV-2(COVID-19)感染(axSpA组7.8/100 PY,PsA组8.8/100 PY)、鼻咽炎(axSpA组8.2/100 PY,PsA组7.7/100 PY)和上呼吸道感染(axSpA组5.0/100 PY,PsA组5.6/100 PY)。
- 口腔念珠菌病EAIR/100 PY在axSpA组为3.7、PsA组为4.2,大多数事件为轻中度;因口腔念珠菌病停用BKZ的EAIR低(axSpA和PsA组均为0.3/100 PY)。
- 未报告系统性真菌感染或活动性结核病例。
- 经判定的确诊/很可能炎症性肠病、葡萄膜炎、经判定的主要不良心血管事件及经判定的自杀意念/行为的EAIR均低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the long-term safety profile of bimekizumab (BKZ) in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). METHODS: Safety data pooled from six integrated phase IIb/III studies in axSpA and PsA are reported (to the July 2022 data-cut for phase III) for patients who received ≥1 dose of BKZ 160 mg every 4 weeks. Treatment-emergent adverse events (TEAEs) are reported using exposure-adjusted incidence rate per 100 patient-years (EAIR/100 PY). RESULTS: The axSpA and PsA safety pools included 848 (total BKZ exposure: 2034.4 PY) and 1407 patients (2590.8 PY), respectively. TEAEs occurred at an EAIR/100 PY of 136.9 in axSpA and 139.6 in PsA; study discontinuation due to TEAEs was low (axSpA: 2.7/100 PY; PsA: 3.1/100 PY). The three most frequently reported TEAEs were SARS-CoV-2 (COVID-19) infection (axSpA: 7.8/100 PY; PsA: 8.8/100 PY), nasopharyngitis (axSpA: 8.2/100 PY; PsA: 7.7/100 PY) and upper respiratory tract infection (axSpA: 5.0/100 PY; PsA: 5.6/100 PY). EAIR/100 PY of oral candidiasis was 3.7 in axSpA and 4.2 in PsA; most events were mild/moderate. EAIR of BKZ discontinuation due to oral candidiasis was low (both axSpA and PsA: 0.3/100 PY). No systemic fungal infections or cases of active tuberculosis were reported. EAIRs of adjudicated definite/probable inflammatory bowel disease, uveitis, adjudicated major adverse cardiovascular events and adjudicated suicidal ideation/behaviour were low. CONCLUSION: Overall, BKZ demonstrated good tolerability, with TEAE EAIRs comparable between axSpA and PsA cohorts, remaining stable over extended treatment periods. No new safety signals were identified. TRIAL REGISTRATION NUMBERS: NCT02963506 (BE AGILE); NCT03355573 (BE AGILE 2); NCT03928704 (BE MOBILE 1); NCT03928743 (BE MOBILE 2); NCT04436640 (BE MOVING); NCT02969525 (BE ACTIVE); NCT03347110 (BE ACTIVE 2); NCT03895203 (BE OPTIMAL); NCT03896581 (BE COMPLETE); NCT04009499 (BE VITAL).
引用
- Mease PJ, Gensler LS, Orbai AM, et al. Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies. RMD Open. 2025. PMID: 40194794. doi:10.1136/rmdopen-2024-005026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。